Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated